US-listed Chinese firms wracked by infighting amid delisting threat

Minority shareholders risk losing out as Sinovac and Hollysys refuse to accept buyout offers. But, seemingly unfazed by the prospect of delisting, will the firms pursue value creation elsewhere?

Over 160 Chinese companies listed on US exchanges face the likelihood of being forced to delist due to a recent US law, but some have rejected buyout offers providing an alternative route privatisation. These include Nasdaq-listed Chinese companies, Sinovac Biotech and Hollysys Automation Technologies, which are yet to follow a concrete path due to internal conflict between shareholders and directors.

The threatening legislation is the Holding Foreign Companies Accountable Act HFCAA, which was signed into law by former US President, Donald Trump, in December 2020 and requires all US-listed firms to appoint a financial auditor recognised by the Federal Reserve-supported Public Company Accounting Oversight Board PCAOB. Before...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 1 article per month from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222

Share our publication on social media
Share our publication on social media